⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of HepaRegeniX GmbH and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
HepaRegeniX GmbH
↗Tübingen, Germany
HepaRegeniX is a clinical-stage biotechnology company based in Tübingen, Germany, focused on developing innovative regenerative therapies for acute and chronic liver diseases. The company's proprietary platform targets Mitogen-Activated Protein Kinase Kinase 4 (MKK4), a key regulator of liver regeneration, to unlock the liver's natural ability to repair itself.
The company's lead candidate, HRX-215, is a first-in-class, orally available small molecule inhibitor. It is currently being evaluated in clinical trials for conditions such as post-hepatectomy liver failure, liver transplantation, and severe alcohol-associated hepatitis. HepaRegeniX is backed by a syndicate of prominent life science investors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Series C
Total Raised:$40M+
Investors:Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund (BIVF), High-Tech Gründerfonds (HTGF), Wellington Partners, coparion, Ascenion GmbH
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 1b/2a
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:University Hospital Tübingen (Discovery collaboration), Mayo Clinic (Preclinical research)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Elias Papatheodorou - CEO
Dr. Wolfgang Albrecht - Managing Director, COO & Co-Founder
Dr. Martin Bonde - Chair of the Board
Scientific Founders:Prof. Lars Zender, Prof. Stefan Laufer, Dr. Wolfgang Albrecht
Board Members:Dr. Martin Bonde, Fabienne Roussel
LINKS
Website:heparegenix.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with HepaRegeniX GmbH. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.